Samjin Pharmaceutical Company

Samjin Pharmaceutical Company, established in 1968 and headquartered in Seoul, Korea, specializes in the research and development of pharmaceutical products. The company focuses on addressing significant health challenges, including dry eye syndrome, HIV, cancer, age-related macular degeneration, and central nervous system disorders. Its product pipeline features several candidates at various stages of development, such as SA001, a clinical Phase II treatment for dry eye syndrome, and SJ-3366, which targets HIV in preclinical and clinical stages. Additionally, Samjin's portfolio includes multiple preclinical and clinical products aimed at treating cancer, rheumatoid arthritis, diabetes, Alzheimer's disease, and anti-coagulation conditions. The company is committed to advancing healthcare by leveraging skilled personnel, innovative materials, and state-of-the-art medical technology to develop effective treatments for various diseases.